Decline depth
-31.6%
From rolling 252-day high of $28.00, 136d ago.
Past the 30% Amber threshold.
-31.6%
from rolling 252-day high of $28.00 set 2026-04-27 · 136d ago
Current
$19.14
Decline depth
-31.6%
Decline σ
8.5σ
TFC
3/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Since it joined the list
$JBIO landed on the list 2026-04-16, down 78.1% from its 52-week high that day — now down -31.6%.
That's 2.8 percentage points deeper than the day it joined. It bottomed 85.0% below that high along the way.
From the 52-week high as of 2026-04-16 to today. Split-adjusted. Observed, not a forecast.
Structural break signals
JBIO qualifies for the Red List on decline depth.
Time-frame continuity
3/5 bearish
Latest bar on five time frames, daily to yearly. Bearish = 2-Down or red 3.
Past the 3/5 Watch threshold.
Decline sigma
8.5σ
Drop over the last 20 bars in units of daily volatility (3.01%/day).
Past the ≥8σ Red List threshold — an extreme move.
The structural read
What price action says about JBIO.
JBIO qualifies for the Red List on decline depth — down -31.6% from its rolling 252-day high. Past 30% with the high set inside the last four months — the recency clause that often precedes further breakdown.
Cross-confirmation: also showing 3/5 bearish time frames.
Cross-confirmation: decline sigma also reads 8.5σ over 20 bars.
Upstream TFC read: weak alignment, current phase daily. Last bar types — daily 2D (green), weekly 2D (red), monthly 1 (red).
Earnings on file: 2026-03-06. Earnings dates don't affect tiering.
Questions about JBIO
What people ask.
Why is JBIO on Broken Stocks?
JBIO qualifies for the Red List on decline depth. It is down -31.6% from its rolling 252-day high of $28.00, set on 2026-04-27 — 136d ago.
Is JBIO a falling knife?
Not by the strict technical definition. JBIO is down -31.6% from its 52-week high, but that high was set 136d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. JBIO is still on the Red List for decline depth, but the freshness component of a falling knife is missing.
Is JBIO a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is JBIO trading inside its 52-week range?
At $19.14, JBIO sits 58.5% of the way from its 52-week low ($6.67) to its 52-week high ($28.00). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has JBIO been declining?
The current 31.6% decline accrued over 136d, which annualizes to roughly -84.8% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does JBIO compare to its sector?
There are 283 other Healthcare tickers on Broken Stocks: 155 Red, 79 Amber, 49 Watch, with 28 showing recovering structural signals. Median sector decline is -36.0% — JBIO's decline is shallower than the sector median.
Does JBIO's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-03-06) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.